The prognosis value of CONUT and SIS score for recurrent or metastatic esophageal squamous cell carcinoma patients treated with second-line immunotherapy.

Zhao, Xiao-Han; Shen, Wen-Bin; Wang, Duo; Wang, He-Song; Song, Chun-Yang; Deng, Wen-Zhao

Zhao, Xiao-Han; Shen, Wen-Bin; Wang, Duo; Wang, He-Song; Song, Chun-Yang; Deng, Wen-Zhao.

Afiliação

Zhao XH; Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Shen WB; Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Wang D; Hebei Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology, College of Life Sciences, Hebei Normal University, Shijiazhuang, China.
Wang HS; Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Song CY; Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Deng WZ; Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

Front Oncol ; 13: 1167625, 2023.

Article em En | MEDLINE | ID: mdl-37388223

Palavras-chave

controlling nutritional status; esophageal squamous cell carcinoma; immune checkpoint inhibitors; prognosis; second-line treatment; systemic inflammation score

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article